Update:Patent enforceability US Case (Temodar)

Teva, in press release, said that the parties to the patent litigation of Barr vs Schering related to Temodar [temozolomide] have entered into an agreement pending resolution of Schering’s appeal to the Federal Circuit of the U.S. District Court’s decision holding the ‘291 Patent unenforceable.

Under the terms of the agreement, subject to limited exceptions, Teva will only market a generic product should the Federal Circuit uphold the District Court’s decision. Furthermore, the agreement grants Teva the right to commence selling its generic product as of August 2013, during the period of Schering’s pediatric exclusivity.

Earlier Post [Link]